Quest for the right Drug
דוריבקס DORIBAX (DORIPENEM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה לאינפוזיה : POWDER FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration The recommended dosage and administration by infection is shown in the following table: Infection Dosage Frequency Infusion Time Complicated intra-abdominal infection 500 mg every 8 hours 1 hour Complicated UTI, including pyelonephritis 500 mg every 8 hours 1 hour The usual treatment duration of doripenem therapy is 5-14 days and should be guided by the severity, site of the infection and the patient’s clinical response. Doripenem was given for up to 14 days in clinical studies and the safety of longer durations of therapy has not been established. After commencing treatment with intravenous doripenem, a switch to appropriate oral therapy to complete the treatment course is possible once clinical improvement has been established. Dosage in paediatric patients Doribax is not recommended for use in children below 18 years of age due to a lack of safety and efficacy data. Dosage in patients with impaired renal function In patients with mild renal impairment (i.e. creatinine clearance (CrCl) is 51-79 ml/min), no dosage adjustment is necessary. In patients with moderate renal impairment (CrCl 30 to <50 ml/min), the dosage of Doribax should be 250 mg every 8 hours. In patients with severe renal impairment (CrCl <30 ml/min), the dosage of Doribax should be 250 mg every 12 hours. Due to limited clinical data and an expected increased exposure of doripenem and its metabolite, Doribax should be used with caution in patients with severe renal impairment (see section 5.2). Doribax PI_08 2008 EL Dosage in patients on dialysis Doribax is haemodialysable; however, there is insufficient information to make dose adjustment recommendations in patients on dialysis. Therefore, Doribax is not recommended for patients on any type of dialysis (see section 5.2). Dosage in elderly patients (65 years of age) No dosage adjustment is necessary in elderly patients, except in cases of moderate to severe renal insufficiency (see Dosage in patients with impaired renal function above and section 5.2). Dosage in patients with impaired hepatic function No dosage adjustment is necessary. Method for administration Doribax is to be reconstituted and then further diluted (see section 6.6) prior to administration by intravenous infusion over a period of one or four hours.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף